Soligenix Inc., a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs. The publication highlights the therapy's safety profile, non-mutagenic mechanism and demonstrated efficacy across studies, while supporting its potential as a first-line treatment option as the company advances its ongoing FLASH2 Phase 3 trial with interim analysis expected in the second quarter of 2026.
The importance of this peer-reviewed publication lies in its validation of HyBryte's clinical data through independent scientific scrutiny. For patients suffering from cutaneous T-cell lymphoma, a rare and often debilitating cancer of the immune system, this represents progress toward a potentially safer and more effective treatment option. The therapy's non-mutagenic mechanism is particularly significant, as it suggests HyBryte may avoid the DNA-damaging effects associated with some existing cancer treatments, potentially reducing long-term risks for patients.
Soligenix's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. The company's development programs also include expansion of synthetic hypericin into psoriasis, and first-in-class innate defense regulator technology for inflammatory diseases.
The company maintains a newsroom where investors can access the latest updates at https://ibn.fm/SNGX. This publication milestone comes as Soligenix continues to advance multiple development programs across its business segments. The Public Health Solutions business segment includes development programs for vaccine candidates targeting ricin toxin, filoviruses such as Marburg and Ebola, and CiVax for COVID-19 prevention. These programs incorporate the company's proprietary heat stabilization platform technology, ThermoVax, and have been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases.
For the biopharmaceutical industry, the publication of comprehensive clinical data in a respected peer-reviewed journal represents an important step in the drug development process, providing independent validation that can support regulatory submissions and eventual market adoption. The interim analysis expected in 2026 for the FLASH2 Phase 3 trial will provide further critical data on HyBryte's efficacy and safety profile. As rare disease treatments often face unique development and regulatory challenges, this publication helps establish the scientific foundation necessary for advancing promising therapies through the approval pipeline.
